Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate
- 6 December 2019
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 28 (8) , 3679-3689
Abstract
Purpose To explore improvement in motor ability, function, health-related quality of life (HRQOL), and symptom severity in patients with sclerotic chronic graft-versus-host disease (ScGVHD) in response to treatment as well as the relationship among changes on such measures. Methods This study was a secondary analysis of data from 13 individuals with severe ScGVHD enrolled in a clinical trial evaluating the efficacy of imatinib mesylate (clinicaltrials.gov identifier: NCT00702689). Self-reported, clinician-reported, and performance-based indicators of motor ability, function, HRQOL, and symptom severity were assessed at baseline and 6 months following the administration of imatinib mesylate. Results Participants did not show statistically significant improvement on any measures over time. Approximately one-third of patients displayed clinically significant improvement on measures of motor ability (palmar pinch strength, dominant hand, 30.8%), functioning (Manual Ability Measure—36, 41.7%), HRQOL (Short Form 36 [SF-36] Mental Component Summary, 33.3%), and symptom severity (Lee Symptom Scale, 38.5%). Improvement in cGVHD symptom burden was correlated with improvement in function (Assessment of Motor and Process Skills [AMPS] and Disabilities of the Arm, Shoulder, and Hand [DASH] scores) and HRQOL (SF-36 Physical Component Summary scores). Conclusions Findings suggest the potential utility of administering patient-reported and performance-based functional measures, such as the DASH and the AMPS, to patients with cGVHD. By understanding the functional consequences of ScGVHD, interdisciplinary teams of health care providers, including rehabilitation professionals, can work to improve long-term outcomes.Keywords
This publication has 40 references indexed in Scilit:
- Participation in cancer rehabilitation and unmet needs: a population-based cohort studySupportive Care in Cancer, 2012
- Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of diseaseBlood, 2011
- Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease ConsortiumHaematologica, 2011
- Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD)Bone Marrow Transplantation, 2009
- Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host diseaseBlood, 2009
- Construct Validity and Reliability of the Disability ofArm, Shoulder and Hand Questionnaire for Upper Extremity Complaints in Rheumatoid ArthritisThe Journal of Rheumatology, 2008
- The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT)Supportive Care in Cancer, 2008
- Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor StudyBlood, 2007
- Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor StudyBlood, 2006
- Physical Function in Patients with CancerJournal of Pain and Symptom Management, 2002